

## [Methotrexate](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01BA01](#)

EMLc

Indication

Acute myeloid leukaemia with recurrent genetic abnormalities ICD11 code: [2A60.0](#)

INN

Methotrexate

Medicine type

Chemical agent

List type

Complementary

Formulations

**Parenteral > General injections > IV:** 50 mg in vial (as sodium salt) ; 50 mg per 2 mL ; 1000 mg per 10 mL concentrated injection

**Oral > Solid:** 2.5 mg (as sodium salt)

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Methotrexate](#)

[DrugBank](#)

[Methotrexate](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of additional dose forms of methotrexate (Injection: 50 mg/2 mL and Concentrated injection: 1000 mg/10 mL) to the EML and EMLc.